Dr. Langmuir Discusses Vandetanib Clinical Trials

Peter Langmuir, MD
Published: Tuesday, Mar 15, 2011

Peter Langmuir, MD, Executive Director, Medical Science AstraZeneca, discusses a phase III double-blind study that investigated the use of vandetanib for 331 patients with unresectable locally advanced or metatastic medullary thyroid cancer.
Peter Langmuir, MD, Executive Director, Medical Science AstraZeneca, discusses a phase III double-blind study that investigated the use of vandetanib for 331 patients with unresectable locally advanced or metatastic medullary thyroid cancer.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x